Actively Recruiting
Risk-Adapted Treatment for Children and Young Adults with Favorable Histology Wilms Tumors Using Tumor Biology and Response
Led by Children's Oncology Group · Updated on 2026-08-25
1656
Participants Needed
169
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
This clinical trial is a phase III study focused on children with favorable histology Wilms tumors FHWT, the most common type of kidney cancer in children. The study aims to improve treatment by using risk factors, including tumor biology and response to therapy, to guide treatment decisions. It seeks to maintain or improve event-free survival EFS while reducing therapy intensity for some patients and comparing different chemotherapy regimens for others based on tumor stage and biology. The study includes various treatment arms depending on tumor stage and risk factors, ranging from nephrectomy only with observation to multiple chemotherapy regimens, including EE-4A, DD-4A, VIVA, MVI, M, and UH-3. Treatments involve combinations of drugs such as vincristine, dactinomycin, doxorubicin, cyclophosphamide, etoposide, carboplatin, and irinotecan given via intravenous infusions on specific schedules. Patients also undergo various imaging procedures like CT, MRI, ultrasound, X-rays, bone scans, and PET scans throughout the study. Participants will be involved in receiving assigned treatments based on their tumor stage and biology, with close monitoring through imaging and laboratory tests during therapy. The study will measure event-free survival up to 4 years from entry as the primary outcome, along with overall survival. After completing treatment, patients will be followed for up to 10 years to monitor long-term outcomes and side effects. The trial is sponsored by the Childrens Oncology Group and involves randomized assignment to different treatment regimens.
CONDITIONS
Brief Title
A Study Using Risk Factors to Determine Treatment for Children With Favorable Histology Wilms Tumors (FHWT)
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here